Background: Mycosis fungoides (MF) is the most common type of cutaneous-T-cell lymphoma, with no established consensus for its treatment. The standardtreatment for early stage MF is PUVA. UVA1 phototherapy was found toinduce marked improvement in skin lesions of patients with stages IA and IBMF. Broad band UVA is composed of 80.1% UVA1, with similar mechanismsof action.Aim of work: The aim of the present work was to compare the efficacy ofPUVA versus broad band UVA as a substitute to UVA1 in the treatment ofearly stage MF (IA, IB, IIA).Patients and methods; Thirty patients with early stage MF (IA and IB) wereincluded in this prospective, randomized clinical trial. They were randomlydivided into two equal groups; group A [15 patients receiving PUVA] andgroup B [15 patients receiving BBUVA at 20J/cm2/ session]. The patientsreceived 3 sessions/week for 13 weeks i.e. forty sessions. The patients werecompared regarding clinical, histopathological, immunohistochemical (Bymeasuring the bcl-2 level) and overall responses.Results: Among each of the two groups, there was statistically significantimprovement in the clinical, histopathological, immunohistochemical andoverall responses. However there was no statistically significant differencebetween both groups in any of the aspects with comparable overall successrates; (93.3%) in the PUVA group and (80%) in the BBUVA group. Excellentoverall response rates was higher in the BB-UVA group (41.7%) versus(14.3%) in the PUVA group, but still with no statistically significant difference(P=0.117).As regards the side effects encountered in both groups; there was nostatistically significant difference in the rates of tanning, pruritus, appearanceof new lesions, photosensitivity or dryness. However discomfort wassignificantly higher among the BB-UVA group (P=0.032) and nausea wassignificantly higher among the PUVA group (P=0.003).Conclusion: BB-UVA is a new, yet promising therapeutic modality in thetreatment of early stage MF, as it is comparable to PUVA, as regards both theefficacy and safety. It could substitute the use of UVA1 in the treatment ofearly stage MF specially in pigmented skin (phototype ≥ III) that can withstandlonger periods of phototherapy without phototoxicity.